Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ARYx Therapeutics has posted a net loss of $2.51m for the third quarter 2010, or $0.08 loss per diluted share, compared to net loss of $8.15m, or $0.30 loss per diluted share, for the comparable period in 2009.
Subscribe to our email newsletter
ARYx‘s loss from operations was $2.15m, compared to $7.63m for the comparable period in 2009.
For the nine months ended 30 September 2010 ARYx posted a net loss of $12.54m, or $0.39 loss per diluted share, compared to $27.38m, or $1 loss per diluted share, for the year ago period.
The company’s loss from operations for the nine months ended 30 September 2010 was $11.41m, compared to $25.92m for the year ago period.
ARYx was awarded a grant totaling $943,900 under the Federal Qualifying Therapeutic Discovery Project (QTDP) program to which the company had applied in July 2010.
ARYx discovers and develops novel drugs for large, chronic disease markets, unresolved by currently available therapies due to limitations in drug design and metabolism problems.